Recursion Pharmaceuticals: Unlocking The Future Of Biotech With AI-Powered Drug DiscoverySeeking Alpha • 06/14/23
Recursion's Phase 2 Trial for the Treatment of Cerebral Cavernous Malformation has Fully EnrolledGlobeNewsWire • 06/13/23
Recursion Pharmaceuticals Is Going Big on AI. Here's Why It Could Be Worth BuyingThe Motley Fool • 05/29/23
Recursion Provides Business Updates and Reports First Quarter 2023 Financial ResultsGlobeNewsWire • 05/08/23
Recursion Enters into Agreements to Acquire Cyclica and Valence to Bolster Chemistry and Generative AI CapabilitiesGlobeNewsWire • 05/08/23
Recursion Publishes Second Annual Environmental, Social and Governance ReportGlobeNewsWire • 03/28/23
Recursion Pharmaceuticals (RXRX) Reports Q4 Loss, Misses Revenue EstimatesZacks Investment Research • 02/28/23
Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2022 Financial ResultsGlobeNewsWire • 02/27/23
Community Leaders Unite to Provide Support and Resources for Thousands of Utahns with Rare DiseasesGlobeNewsWire • 02/21/23
Bears are Losing Control Over Recursion Pharmaceuticals (RXRX), Here's Why It's a 'Buy' NowZacks Investment Research • 01/27/23
Recursion Releases MolRec, a Compound Intelligence Tool for Drug Discovery, Alongside the Largest of Its Kind Open-Source Dataset During First R&D DayPRNewsWire • 01/26/23
Recursion Pharmaceuticals (RXRX) Upgraded to Buy: What Does It Mean for the Stock?Zacks Investment Research • 01/25/23
How Much Upside is Left in Recursion Pharmaceuticals (RXRX)? Wall Street Analysts Think 53.67%Zacks Investment Research • 01/25/23
Recursion Provides Business Updates and Reports Third Quarter 2022 Financial ResultsPRNewsWire • 11/08/22
Recursion Announces $150 Million Private Placement to New and Existing Investors, led by Kinnevik ABPRNewsWire • 10/25/22
Recursion Receives ISS ESG Prime Rating and Plans to Participate in the Goldman Sachs Global Sustainability ForumPRNewsWire • 08/18/22
Recursion Provides Business Updates and Reports Second Quarter 2022 Financial ResultsPRNewsWire • 08/09/22
Recursion is Granted EU Orphan Drug Designation for REC-4881 for the Potential Treatment of Familial Adenomatous PolyposisPRNewsWire • 07/21/22